United States - English - NLM (National Library of Medicine)

orchidpharma inc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules are indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes . cephalexin capsules are indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae, staphylococcus aureus, streptococcus pyogenes, and moraxella catarrhalis . cephalexin capsules are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin capsules are indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis . cephalexin capsules are indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli, proteus mirabilis, and klebsiella pneumoniae . to reduce the development of drug-resist

United States - English - NLM (National Library of Medicine)

orchidpharma inc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg

United States - English - NLM (National Library of Medicine)

orchidpharma inc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 125 mg in 5 ml - cephalexin for oral suspension, usp is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin for oral suspension, usp is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis genitourinary tract infections, including

United States - English - NLM (National Library of Medicine)

orchidpharma inc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg - granisetron hydrochloride tablets are indicated for the prevention of: - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.

United States - English - NLM (National Library of Medicine)

orchidpharma, inc - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with naratriptan tablets, reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. - naratriptan tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of naratriptan tablets have not been established for cluster headache. naratriptan tablets are contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1)] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2)] - history of stroke

United States - English - NLM (National Library of Medicine)

orchidpharma inc - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine headache has been established. if a patient has no response to the first migraine attack treated with sumatriptan, reconsider the diagnosis of migraine before sumatriptan is administered to treat any subsequent attacks. - sumatriptan is not indicated for the prevention of migraine attacks. - safety and effectiveness of sumatriptan tablets have not been established for cluster headache. sumatriptan tablets are contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1)] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2)] - history of stroke or transient isc

United States - English - NLM (National Library of Medicine)

orchid healthcare (a division of orchid chemicals and pharmaceuticals ltd.) - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - tablet, film coated - 125 mg - divalproex sodium is indicated for the treatment of the manic episodes associated with bipolar disorder. a manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgement, aggressiveness, and possible hostility. the efficacy of divalproex sodium was established in 3 week trials with patients meeting dsm-iii-r criteria for bipolar disorder who were hospitalized for acute mania (see clinical trials under clinical pharmacology ). the safety and effectiveness of divalproex sodium for long-term use in mania, i.e., more than 3 weeks, has not been systematically evaluated in controlled clinical trials. therefore, physicians who elect to use divalproex sodium for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. divalproex sodium is indicated as monotherapy and adjunctive

United States - English - NLM (National Library of Medicine)

kosan kozmetik sanayi ve ticaret a.s. - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - titanium dioxide 20 mg in 1 g - - helps prevent sunburn - if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

orchid healthcare (a division of orchid chemicals and pharmaceuticals ltd.) - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - injection, powder, for solution - 10 g - cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of streptococci.

United States - English - NLM (National Library of Medicine)

orchid healthcare (a division of orchid chemicals and pharmaceuticals ltd.) - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - 250 mg